CA2638828C - Immunomodulatory and anti-tumor peptides derived from lalf - Google Patents
Immunomodulatory and anti-tumor peptides derived from lalf Download PDFInfo
- Publication number
- CA2638828C CA2638828C CA2638828A CA2638828A CA2638828C CA 2638828 C CA2638828 C CA 2638828C CA 2638828 A CA2638828 A CA 2638828A CA 2638828 A CA2638828 A CA 2638828A CA 2638828 C CA2638828 C CA 2638828C
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- peptides
- lps
- tumor
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 131
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 61
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 28
- 230000002519 immonomodulatory effect Effects 0.000 title claims abstract description 14
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 53
- 201000011510 cancer Diseases 0.000 claims abstract description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 8
- 229920000669 heparin Polymers 0.000 claims description 19
- 229960002897 heparin Drugs 0.000 claims description 18
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 17
- 108010009352 antilipopolysaccharide factor (Limulus) Proteins 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 230000015788 innate immune response Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 150000002270 gangliosides Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 abstract description 31
- 229920006008 lipopolysaccharide Polymers 0.000 abstract description 31
- 235000001014 amino acid Nutrition 0.000 abstract description 9
- 238000006467 substitution reaction Methods 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 5
- 238000011443 conventional therapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 18
- 238000003556 assay Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 210000004443 dendritic cell Anatomy 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 108010065805 Interleukin-12 Proteins 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 108010014726 Interferon Type I Proteins 0.000 description 6
- 102000002227 Interferon Type I Human genes 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 241000701806 Human papillomavirus Species 0.000 description 5
- 102000013462 Interleukin-12 Human genes 0.000 description 5
- 102000002689 Toll-like receptor Human genes 0.000 description 5
- 108020000411 Toll-like receptor Proteins 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 229940117681 interleukin-12 Drugs 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241001529936 Murinae Species 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 3
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 229940021747 therapeutic vaccine Drugs 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241001529572 Chaceon affinis Species 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000029662 T-helper 1 type immune response Effects 0.000 description 2
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 2
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- -1 anti-coagulation Chemical compound 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- OVXIMRGEBNSORH-UHFFFAOYSA-N 2-[[2-[2-[[2-[[1-[1-[5-amino-2-[[2-amino-3-(1h-indol-3-yl)propanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoylamino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylp Chemical compound CCC(C)C(C(O)=O)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C1N(C(=O)C(CCC(N)=O)NC(=O)C(N)CC=2C3=CC=CC=C3NC=2)CCC1 OVXIMRGEBNSORH-UHFFFAOYSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 1
- 206010020608 Hypercoagulation Diseases 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710092489 Protein kinase 2 Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 108010072542 endotoxin binding proteins Proteins 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000594 epithelial cell of lung Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 101150086609 groEL2 gene Proteins 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003027 hypercoagulation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000012116 immunodeficiency-related disease Diseases 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20060047A CU23582A1 (es) | 2006-02-24 | 2006-02-24 | Péptidos con capacidad anti-tumoral e inmunomoduladora |
| CU2006-0047 | 2006-02-24 | ||
| PCT/CU2007/000006 WO2007095867A1 (es) | 2006-02-24 | 2007-02-23 | Peptidos con capacidad anti-tumoral e inmunomoduladora |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2638828A1 CA2638828A1 (en) | 2007-08-30 |
| CA2638828C true CA2638828C (en) | 2014-09-09 |
Family
ID=38123823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2638828A Expired - Fee Related CA2638828C (en) | 2006-02-24 | 2007-02-23 | Immunomodulatory and anti-tumor peptides derived from lalf |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8283324B2 (enExample) |
| EP (1) | EP1992638B1 (enExample) |
| JP (1) | JP5069250B2 (enExample) |
| KR (1) | KR101456205B1 (enExample) |
| CN (1) | CN101426813B (enExample) |
| AR (1) | AR059608A1 (enExample) |
| AT (1) | ATE493434T1 (enExample) |
| AU (1) | AU2007218671B2 (enExample) |
| BR (1) | BRPI0708148B1 (enExample) |
| CA (1) | CA2638828C (enExample) |
| CU (1) | CU23582A1 (enExample) |
| ES (1) | ES2358845T3 (enExample) |
| MX (1) | MX2008010893A (enExample) |
| RU (1) | RU2430109C2 (enExample) |
| WO (1) | WO2007095867A1 (enExample) |
| ZA (1) | ZA200807034B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23674A1 (es) * | 2007-07-31 | 2011-05-27 | Ct Ingenieria Genetica Biotech | Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica |
| EP2108372A1 (en) * | 2008-04-09 | 2009-10-14 | Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften | Novel antimicrobial peptides |
| US20120237535A1 (en) * | 2009-09-11 | 2012-09-20 | Proyecto De Biomedicina Cima, S.L. | Therapeutic Compositions For The Treatment of HPV-Induced Diseases |
| CU23897B1 (es) * | 2010-05-31 | 2013-05-31 | Ct De Ingeniería Genética Y Biotecnología | Péptido para la terapia del cáncer |
| CN103724412A (zh) * | 2013-09-29 | 2014-04-16 | 中国科学院海洋研究所 | 中国明对虾抗脂多糖因子及其制备和应用 |
| WO2024006746A1 (en) * | 2022-06-29 | 2024-01-04 | Cdres Pharma Llc | Immunologically active polypeptide |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2146667A1 (en) | 1993-08-18 | 1995-02-23 | Adolf Hoess | Lipopolysaccharide-binding and neutralizing peptides |
| CU22700A1 (es) | 1997-09-29 | 2001-07-31 | Ct Ingenieria Genetica Biotech | Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso |
| WO2002038164A1 (en) | 2000-11-08 | 2002-05-16 | Lorus Therapeutics Inc. | Combination preparation of a biological response modifier and an anticancer agent and uses thereof |
-
2006
- 2006-02-24 CU CU20060047A patent/CU23582A1/es unknown
-
2007
- 2007-02-22 AR ARP070100749A patent/AR059608A1/es not_active Application Discontinuation
- 2007-02-23 EP EP07711100A patent/EP1992638B1/en active Active
- 2007-02-23 RU RU2008137968/04A patent/RU2430109C2/ru not_active IP Right Cessation
- 2007-02-23 CA CA2638828A patent/CA2638828C/en not_active Expired - Fee Related
- 2007-02-23 AU AU2007218671A patent/AU2007218671B2/en not_active Ceased
- 2007-02-23 ES ES07711100T patent/ES2358845T3/es active Active
- 2007-02-23 CN CN2007800138842A patent/CN101426813B/zh not_active Expired - Fee Related
- 2007-02-23 US US12/278,990 patent/US8283324B2/en not_active Expired - Fee Related
- 2007-02-23 MX MX2008010893A patent/MX2008010893A/es active IP Right Grant
- 2007-02-23 AT AT07711100T patent/ATE493434T1/de not_active IP Right Cessation
- 2007-02-23 KR KR1020087023166A patent/KR101456205B1/ko not_active Expired - Fee Related
- 2007-02-23 WO PCT/CU2007/000006 patent/WO2007095867A1/es not_active Ceased
- 2007-02-23 BR BRPI0708148A patent/BRPI0708148B1/pt not_active IP Right Cessation
- 2007-02-23 JP JP2008555601A patent/JP5069250B2/ja not_active Expired - Fee Related
-
2008
- 2008-08-14 ZA ZA200807034A patent/ZA200807034B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200807034B (en) | 2009-06-24 |
| AR059608A1 (es) | 2008-04-16 |
| AU2007218671B2 (en) | 2012-02-09 |
| AU2007218671A1 (en) | 2007-08-30 |
| CA2638828A1 (en) | 2007-08-30 |
| CN101426813B (zh) | 2012-04-04 |
| RU2008137968A (ru) | 2010-03-27 |
| JP5069250B2 (ja) | 2012-11-07 |
| KR101456205B1 (ko) | 2014-10-31 |
| ATE493434T1 (de) | 2011-01-15 |
| US20090221508A1 (en) | 2009-09-03 |
| WO2007095867A1 (es) | 2007-08-30 |
| RU2430109C2 (ru) | 2011-09-27 |
| EP1992638A1 (en) | 2008-11-19 |
| CN101426813A (zh) | 2009-05-06 |
| CU23582A1 (es) | 2010-10-30 |
| BRPI0708148A2 (pt) | 2011-05-17 |
| ES2358845T3 (es) | 2011-05-16 |
| JP2009527510A (ja) | 2009-07-30 |
| EP1992638B1 (en) | 2010-12-29 |
| US8283324B2 (en) | 2012-10-09 |
| KR20080106446A (ko) | 2008-12-05 |
| MX2008010893A (es) | 2008-09-03 |
| BRPI0708148B1 (pt) | 2019-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023106599A (ja) | タンパク質抗原およびその使用 | |
| JP5294271B2 (ja) | Ｃｄｈ３ペプチド及びこれを含む薬剤 | |
| CA2638828C (en) | Immunomodulatory and anti-tumor peptides derived from lalf | |
| US7846651B2 (en) | Epitope/peptide recognized by HLA-A2402-restricted Ep-CAM-specific CTL and use of the same | |
| JP5789820B2 (ja) | 血管内皮増殖因子受容体１に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン | |
| WO2016143816A1 (ja) | Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 | |
| CN107530432B (zh) | 药物 | |
| WO2023163094A1 (ja) | 成人ｔ細胞白血病の治療又は予防のための医薬組成物 | |
| TW202544022A (zh) | 源自SARS-CoV-2蛋白之胜肽及含其之疫苗 | |
| JP2006008638A (ja) | サバイビン由来のｈｌａ−ａ２４結合性癌抗原ペプチド | |
| WO2017170365A1 (ja) | 免疫誘導剤 | |
| WO2016175309A1 (ja) | 免疫誘導剤 | |
| HK1141832A (en) | Cdh3 peptide and medicinal agent comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20210831 |
|
| MKLA | Lapsed |
Effective date: 20200224 |